Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes
- First Posted Date
- 2010-04-21
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 29
- Registration Number
- NCT01107899
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, Germany
A Study in Participants With Moderate to Severe Psoriasis
- Conditions
- Psoriasis
- Interventions
- Biological: IxekizumabDrug: Placebo
- First Posted Date
- 2010-04-21
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 142
- Registration Number
- NCT01107457
- Locations
- 🇩🇰
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kobenhavn, Denmark
Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer
- First Posted Date
- 2010-04-21
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 180
- Registration Number
- NCT01107444
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
- Conditions
- Dyslipidemia
- Interventions
- Drug: LY2484595Drug: SimvastatinDrug: Placebo for LY2484595Drug: Placebo for StatinsDrug: AtorvastatinDrug: Rosuvastatin
- First Posted Date
- 2010-04-19
- Last Posted Date
- 2018-03-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 398
- Registration Number
- NCT01105975
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, United Kingdom
Study in Advanced Solid Tumors
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2010-04-07
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 47
- Registration Number
- NCT01099358
- Locations
- 🇺🇸
University of Texas Health Science Center - San Antonio, San Antonio, Texas, United States
🇨🇦For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
A Study in Men With Benign Prostatic Hyperplasia
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Drug: LY500307Drug: Placebo
- First Posted Date
- 2010-04-02
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 414
- Registration Number
- NCT01097707
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation
A Study for Adolescents With Fibromyalgia Syndrome
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT01089621
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States
A Study in Painful Diabetic Neuropathy
- Conditions
- Diabetic Neuropathy, Painful
- Interventions
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 811
- Registration Number
- NCT01089556
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chorley, United Kingdom
Zyprexa® Relprevv™ Patient Care Program
- Conditions
- Schizophrenia
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 4000
- Registration Number
- NCT01088386
- Locations
- 🇺🇸
United BioSource Corporation, Blue Bell, Pennsylvania, United States
Observational Study of Somatropin Treatment in Children
- Conditions
- Short Stature Homeobox Containing Gene (SHOX) DeficiencySHOX Deficiency-related DisorderNon-GH-deficient Growth DisordersGrowth Hormone (GH) Deficiency
- Interventions
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 22845
- Registration Number
- NCT01088412